The global anti-idiopathic pulmonary fibrosis drugs market in 2020 is estimated for more than US$ 2,730.5 Mn and expected to reach a value of US$ 10,194.4 Mn by 2028 with a significant CAGR of 18.1%
An overview of conceptual frameworks, analytical approaches of the Anti-Idiopathic Pulmonary Fibrosis Drugs Market is the main objective of the report, which further consists of the market opportunity and insights of the data involved in the making of the respective market. Anti-Idiopathic Pulmonary Fibrosis Drugs Market is expected to grow at significant rate in the near future.
The global anti-idiopathic pulmonary fibrosis drugs market in 2020 is estimated for more than US$ 2,730.5 Mn and expected to reach a value of US$ 10,194.4 Mn by 2028 with a significant CAGR of 18.1%.
Growing prevalence of idiopathic pulmonary fibrosis (IPF), coupled with increasing geriatric population across the globe are major factors that are expected to drive the growth of the global anti-idiopathic pulmonary fibrosis drugs market during the forecast period. For instance, according to the World Population Aging Report 2015 by United Nations, total population aged 60 years and above is expected to grow by 56%, i.e., from 901 Mn in 2015 to 1.4 Bn in 2030. Also, commercialization of novel drugs is another important factor boosting growth of the target market.
Furthermore, surge in cigarette smoking population is expected to propel the growth of the market in the near future. Moreover, presence of strong pipeline provided by the government for the treatment is likely to increase the growth of global anti-idiopathic pulmonary fibrosis drugs market. However, unknown disease etiology, there is no specific cure for idiopathic pulmonary fibrosis, which is restraining the growth of the target market.
Anti-idiopathic pulmonary fibrosis drugs market is segmented on the basis of market drugs, mechanism of action, innovator and off-label drugs, and by region.
More than 200 diseases related to lungs mainly belong to Idiopathic pulmonary fibrosis (IPF) which is known as interstitial lung diseases (ILDs), which is characterized by the involvement of the tissues which are found in between air sacs of the lung also known as lung interstitium. IPF is one specific presentation of idiopathic interstitial pneumonia (IIP), which is in turn a type of ILD, also called diffuse parenchymal lung disease (DPLD).
Idiopathic pulmonary fibrosis (IPF) is a progressive disease in which the lungs get affected and get scars and marks in tissues and affect lungs performance in a negative manner. Persistent non-productive cough and dyspnea are the most common symptoms and signs of idiopathic pulmonary fibrosis. Also, gradual weight loss and loss of appetite is also found in many individuals due to idiopathic pulmonary fibrosis. IPF mainly occurs in older adults.
However, the causes are unknown. It has been noted that idiopathic pulmonary fibrosis is prevailing more in the smoking population. People also suffer from lung diseases due to second-hand smoking which is the smoke that fills restaurants, offices or other enclosed spaces when people burn tobacco products such as cigarettes, bidis, and water-pipes.
According to a study done by WHO, in May 2019, In adults, second-hand smoke causes serious cardiovascular and respiratory diseases, including coronary heart disease and lung cancer. In infants, it raises the risk of sudden infant death syndrome. In pregnant women, it causes pregnancy complications and low birth weight. Second-hand smoke causes more than 1.2 million premature deaths per year. Also, more than 65,000 children die every year from illnesses attributable to second-hand smoke.
Some of the key participating players in the anti-idiopathic pulmonary fibrosis drugs market are Actelion, Afferent Pharmaceuticals, Asahi Kasei Pharma, Bellerophon Therapeutics, Biogen, Boehringer Ingelheim, FibroGen, Galecto Biotech, Genentech, Global Blood Therapeutics, GSK, and Kadmon Pharmaceuticals and others.
